News & Updates

Induction therapy with guselkumab, an interleukin-23 p19 subunit antagonist, results in clinical and symptomatic remission, as well as other endoscopic improvements in patients with moderate-to-severe active ulcerative colitis (UC), according to the QUASAR study presented at DDW 2023.

Exposure of senaparib, a highly potent poly-(ADP-ribose) polymerase 1/2 inhibitor and CYP3A4 substrate, is significantly increased when administered along with itraconazole and significantly decreased when taken together with rifampicin, reports a recent study involving healthy male volunteers (HMV) in China.

Family-based adverse childhood experiences among women contribute to lower urinary tract symptoms and impact against bladder health during adulthood, suggests a study.

New drug applications approved by US FDA as of 01-15 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with ataluren improves ambulatory function, as assessed by the 6-minute walk distance (6MWD) test, among boys with nonsense mutation Duchenne muscular dystrophy (nmDMD), according to the subgroup analysis of Study 041 trial presented at AAN 2023.